You are here: Industry Insights > Market News > Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Aildenafil Citrate Tablets

Retatrutide 2381089-83-2

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies

pharmaceutical-technologyJuly 10, 2017

Tag: ImmunoPrecise Antibodies , Pharmaceuticals International

Favorites

Valeant Pharmaceuticals International has announced the sale of its subsidiary Dendreon Pharmaceuticals for $819.9m to Sanpower Group.

The divestiture is part of the Canadian company’s plans to simplify its business and reduce debt.

ImmunoPrecise Antibodies has announced the private placement of four million shares priced at C$1 ($0.77) each to raise C$4m ($3.08m).

ImmunoPrecise is a Canadian-based provider of antibodies that plans to use the funds to acquire U-Protein Express.

Previous:Celgene to acquire rights to BeiGene’s PD-1 inhibitor for solid tumour cancers

Next:M&As this week: Acino Pharma, Oriola-KD Corporation, ImmunoPrecise Antibodies

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

PRNewswireDecember 18, 2024

Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies | Pharmasources.com

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

You may like
More>>

Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

You may likeMore>>

You may like
More>>